Lemtrada

Type: Product
Name: Lemtrada
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Report: Over Half of MS Patients Treated With Tecfidera Have Experienced Minor Side Effects

Lemtrada and ocrelizumab will likely be reserved for aggressive/severe MSDecision Resources Group, a health care research firm located in Burlington, Mass., finds that more than half of audited patients with multiple sclerosis (MS) currently treated with ... [Published PT Community - Jul 23 2014]
First reported Jul 20 2014 - Updated Jul 20 2014 - 1 reports

7/20/14 - Genzyme's Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis

By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) ... [Published Pharmacy Choice - Jul 20 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

BTG PLC : Interim Management Statement

BTG plc: Interim Management Statement and Annual General MeetingLondon, UK, 16 July 2014:Trading during the period has been in line with the Board's expectations across all business segments. Full year revenue is expected to be in the £330m to £345m range ... [Published Investegate - Jul 16 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

GENZYME : Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis

By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Genzyme , a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced that Argentina's National Administration of Drugs , Food and Medical Technology (ANMAT) has approved LemtradaTM ... [Published 4 Traders - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Scottish cancer patients denied Imnovid

People in Scotland with the blood cancer multiple myeloma should not have access to Celgene's Imnovid at its current price, according to the Scottish Medicines Consortirum (SMC).The decision was published in the latest round-up of decisions from the SMC, ... [Published PMLive - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Hope for MS sufferers as new treatment is approved for NHS

The Scottish Medicines Consortium (SMC) ruled that the multiple sclerosis (MS) drug Lemtrada is cost-effective for NHS patients despite its 56 000-pound price, The Herald reported Tuesday. "This is a highly effective drug," commented Belinda Weller, ... [Published FirstWord Pharma - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

SMC negative on Celgene’s Imnovid for MM but approves Genzyme’s Lemtrada for MS

The Scottish Medicines Consortium has issued guidance not to recommend US biotech company Celgene’s (Nasdaq: CELG) drug Imnovid (pomalidomide) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior ... [Published Pharma Letter - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 4 reports

Hope for MS sufferers as new treatment is approved for NHS

Alemtuzumab, also known as Lemtrada, can be used to treat NHS patients after it was ruled to be good value for money, despite a £56,000 price tag. An estimated 9,500 people in Scotland who have the more common relapsing remitting form of MS will become ... [Published NewsRT.co.uk - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

SMC Says Yes to Lemtrada®▼ (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple …

"Scotland has one of the highest rates of multiple sclerosis in the world, and the approval of Lemtrada in Scotland is an important step forward for people with active RRMS who remain in need of new treatment options. MS treatments have come a long way ... [Published Yahoo! Finance - Jul 07 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Genzyme gets approval for Lemtrada in Argentina to treat multiple sclerosis

Genzyme has secured approval from Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) for its Lemtrada (alemtuzumab) to treat patients with multiple sclerosis. ... [Published PBR - News - Jul 02 2014]
First reported Jun 30 2014 - Updated Jul 01 2014 - 6 reports

Genzyme reports Lemtrada's approval in Argentina for multiple sclerosis

Genzyme reported on Monday the receipt of approval for Lemtrada (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features in Argentina from the Argentina's National ... [Published Individual.com - Jul 01 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Lemtrada: Long term data on safety and efficacy published

Results from a long-term follow up study of people taking Lemtrada ( alemtuzumab ) have shown that the majority of people on the treatment experienced an overall improvement or stabilisation in disability over seven years .  read more ... [Published MS News - Jun 26 2014]

Quotes

..."We are pleased by the continued global support for Lemtrada," said Genzyme President and CEO, David Meeker. "We are launching the treatment in more than 30 countries this year, and look forward to additional approvals where Lemtrada is still under review." The Lemtrada clinical development program included two randomized Phase III studies comparing treatment with Lemtrada to high-dose subcutaneous interferon...
Louise Makin, BTG's CEO commented: "We have made a good start to the financial year, with revenues across the business growing as expected. The controlled launch of Varithena® in the US reimbursed sector is progressing well and the first patients are scheduled for treatment this quarter. We are implementing plans to expand direct sales of TheraSphere® and the EKOS products in Europe and to expand the availability of the interventional oncology products in Asia. These activities, together with the continued contribution from our specialty pharmaceuticals business and the financial underpin from our royalties, means we are well positioned to deliver sustainable profitable growth."
"The drug is proven to be safe and effective in treating MS and for many people it will be much easier to live with because it's taken in a pill form."
Brendan Martin, general manager for Genzyme UK and Ireland, said: “ "We are thrilled by today's news that the SMC has approved Lemtrada for NHS use for people with RRMS. We are also immensely proud of our association with Lemtrada as a home-grown product, developed and pioneered in Cambridge by a team of UK scientists. This reminds us of the UK's position at the forefront of science-led medicine, the importance of industry collaboration which brings global expertise in clinical development and our joint commitment to MS patients.”"

More Content

All (97) | News (37) | Reports (0) | Blogs (44) | Audio/Video (0) | Fact Sheets (0) | Press Releases (15)
sort by: Date | Relevance
Report: Over Half of MS Patients Treated With T... [Published PT Community - Jul 23 2014]
7/20/14 - Genzyme's Lemtrada Approved in Argent... [Published Pharmacy Choice - Jul 20 2014]
BTG PLC : Interim Management Statement [Published Investegate - Jul 16 2014]
MS pill Tecfidera available on NHS in England a... [Published Noodls - Jul 11 2014]
BREAKING NEWS: NICE OK for Biogen MS pill Tecfi... [Published Pharma Times - Jul 11 2014]
GENZYME : Lemtrada Approved in Argentina for Tr... [Published 4 Traders - Jul 09 2014]
Scottish cancer patients denied Imnovid [Published PMLive - Jul 09 2014]
Hope for MS sufferers as new treatment is appro... [Published FirstWord Pharma - Jul 08 2014]
SMC negative on Celgene’s Imnovid for MM but ap... [Published Pharma Letter - Jul 08 2014]
Hope for MS sufferers as new treatment is appro... [Published NewsRT.co.uk - Jul 08 2014]
Scotland rejects Celgene myeloma drug Imnovid [Published Pharma Times - Jul 08 2014]
New MS drug Lemtrada approved for use in Scotland [Published Noodls - Jul 07 2014]
SMC says yes to alemtuzumab (Lemtrada) [Published Multiple Sclerosis Trust - Jul 07 2014]
SMC Says Yes to Lemtrada®▼ (alemtuzumab) 12mg I... [Published Yahoo! Finance - Jul 07 2014]
New MS drug Lemtrada approved for use in Scotland [Published MS News - Jul 07 2014]
Argentina approves Genzyme’s Lemtrada for multi... [Published Pharmaceutical Technology - Jul 02 2014]
Genzyme gets approval for Lemtrada in Argentina... [Published PBR - News - Jul 02 2014]
Pharmaxis for Prix Galien UK award [Published Bio Spectrum Asia - Jul 01 2014]
Genzyme reports Lemtrada's approval in Argentin... [Published Individual.com - Jul 01 2014]
Genzyme expands its market for MS drug in Latin... [Published Business First of Buffalo - Jun 30 2014]
Genzyme Corporation???s Lemtrada Approved In Ar... [Published BioSpace - Jun 30 2014]
Argentina is the latest country to approve Genz... [Published Boston Globe - Jun 30 2014]
ANMAT approves Genzyme’s Lemtrada for treatment... [Published News-Medical.Net - Jun 30 2014]
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Genzyme Press Release - Jun 30 2014]
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Business Wire Health News - Jun 30 2014]
Pharmaxis short-listed for Prix Galien UK award [Published Australian Life Scientist - Jun 30 2014]
Follow-up: MS patient praises decision to recon... [Published al.com - Jun 26 2014]
Lemtrada: Long term data on safety and efficacy... [Published MS News - Jun 26 2014]
Shortlist announced for best new pharma product [Published Pharmafocus - Jun 24 2014]
XBiotech Announces Addition of Vice President o... [Published Wall Street Select - Jun 23 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
New MS drug Lemtrada approved for use in Scotland [Published MS News - Jul 07 2014]
The new MS drug Lemtrada (also known as alemtuzumab) has received a stamp of approval from Scottish Medicines Consortium (SMC). This means it will be made available on the NHS in Scotland for people with active relapsing remitting MS . Major step ...
Genzyme gets approval for Lemtrada in Argentina... [Published PBR - News - Jul 02 2014]
Genzyme has secured approval from Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) for its Lemtrada (alemtuzumab) to treat patients with multiple sclerosis. ...
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Business Wire Health News - Jun 30 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with ...
Lemtrada: Long term data on safety and efficacy... [Published MS News - Jun 26 2014]
Results from a long-term follow up study of people taking Lemtrada ( alemtuzumab ) have shown that the majority of people on the treatment experienced an overall improvement or stabilisation in disability over seven years .  read more ...
AAN 2014 – New MS treatment studies: Part II [Published MSology - Jun 12 2014]
To continue our coverage of the 2014 annual meeting of the American Academy of Neurology, the following are some of the treatment studies that were presented. To see Part I of this report, click here.     Aubagio (teriflunomide): An analysis ...
1 2 3 4 5 6 7 8 9

Press Releases

sort by: Date | Relevance
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Genzyme Press Release - Jun 30 2014]
Genzyme’s Lemtrada Resubmission Accepted for Re... [Published Genzyme Press Release - May 30 2014]
Genzyme’s Lemtrada Resubmission Accepted for Re... [Published Sanofi.com - Last press releases - May 30 2014]
Genzyme’s Lemtrada Recommended for Reimbursemen... [Published Genzyme Press Release - May 28 2014]
Sanofi: Slowing of Brain Atrophy and Reductions... [Published GlobeNewswire: Advertising News - Apr 30 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.